Q2 2025 Organogenesis Holdings Inc Earnings Call Transcript

Aug 7, 2025 / 09:00 PM GMT

Release Date Price: $4.52 (+0.44%)

Transcript 10-Q8-K

Key Points

Positve

Organogenesis Holdings Inc (ORGO) delivered sales results within the guidance range, driven by better-than-expected growth in surgical and sports medicine products.
The company is optimistic about the proposed CMS payment reform for 2026, which could significantly benefit their products like Applegraph and Dermograph.
Organogenesis Holdings Inc (ORGO) has a strong history of advocating for health policy reform, which aligns with the proposed CMS changes.
The company is expanding its bio-manufacturing capabilities, which is expected to enhance long-term growth and margin profile.
Organogenesis Holdings Inc (ORGO) is on track with its Renew program, targeting a significant market of over 30 million Americans with knee osteoarthritis.

Negative

Net product revenue for the second quarter was down 23% year-over-year, reflecting challenges in the market.
Advanced wound care net product revenue decreased by 25%, impacted by aggressive competitive pricing and market disruptions.
Gross profit margin decreased to 73% from 78% last year, due to lower revenue over fixed costs and product expiration issues.
The company reported a GAAP net loss of $9.4 million for the second quarter, compared to a net loss of $17 million last year.
Organogenesis Holdings Inc (ORGO) adjusted its 2025 revenue guidance downward, reflecting uncertainties and aggressive market conditions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ORGO.OQ - Organogenesis Holdings Inc
Q2 2025 Organogenesis Holdings Inc Earnings Call
Aug 07, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by. Welcome.

Welcome ladies and gentlemen to the 2nd quarter of 2025 earnings conference call for Organo Genesis Holdings Inc. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risk and uncertainties described in the company's filings

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.